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Background
HIV-infected patients harbouring a lamivudine-resistant virus,
seem to take benefit from a continued lamivudine monother-
apy, versus combined antiretroviral treatment (cART) inter-
ruption, since a reduced HIV replication is selected by the
maintenance of lamivudine-related M184 mutation. The
mid-term outcome of isolated lamivudine therapy in multi-
drug-resistant patients with very restricted therapeutic
options, waiting for novel drug classes, is reported.
Methods
Six patients aged 23-49 years (4 males and 2 females, one of
them with perinatal infection), with HIV disease treated
since 13.8 ± 6.2 years with 10.3 ± 4.7 therapeutic lines,
experienced repeated virological-immunological failures due
to an extensive HIV genotype resistance, which finally led
to a complete 3-class resistance, and no residual therapeutic
options, when excluding the use of a fusion/integrase/co-
receptor inhibitors, without the possibility to optimize the
therapeutic background. A concurrent toxicity was also pre-
sent:combined lipodistrophy syndrome, dyslipidemia, and
insulin resistance (3,2, and one patients, respectively).
Results
At the time of lamivudine monotherapy initiation, the
median viremia was 36,000 HIV-RNA copies/mL, while
the median CD4+ count was 344 cells/μL. Despite a pre-
vious diagnosis of AIDS in 4/6 patients, at the time of
therapeutic switch the clinical situation was stable. During
the monthly follow-up with lamivudine monotherapy,
ranging from 8 to 24 months (mean 9.9 ± 5.2) months, no
HIV-associated signs-symptoms occurred, previous cART-
associated laboratory toxicity significantly ameliorated,
and no significant differences were found as to virological-
immunological markers of HIV disease. A fluctuating vire-
mia was noticed in all cases, with a median value at the
end of follow-up of 44,000 HIV-RNA copies/mL, while no
significant loss of CD4+ count occurred (median final
levels:322 cells/μL). Two-four nucleos(t)ide mutations, and
2-5 protease mutations were deselected during the follow-
up, but the M184 mutation remained. All these patients
were allowed to re-introduce a cART with novel drug
classes, according to the availability of an optimized thera-
peutic background in the subsequent months.
Discussion
When extensive HIV resistance does not leave therapeu-
tic options, lamivudine monotherapy performed with a
strict monitoring in clinically stable patients with no
compromised virological-immunological figures, is a
potentially safe choice. Waiting for the novel cART
associations, the exploitment of lamivudine resistance
on HIV replication-fitness represents an ultimate thera-
peutic approach to these difficult-to-manage subjects.
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